|  |  |
| --- | --- |
| **SDC 1. Clinical and epidemiological data of the patients included in the study** |  |
|  | **Uninfected controls** | **BFA-HAART-** | **BFA-HAART+** | **BFA+HAART-** | **BFA+HAART+**  |  **p** |
| Sample size (n) | 24 | 16 | 26 | 6 | 21 |  |
| Mean age ± SEM (years)  | 10.90±1.18 | 12.45±1.22 | 10.13±1.21 | 13.50±1.60 | 14.43±0.46 | NS |
| Male gender (%) | 66 | 62 | 50 | 83 | 29 | (†) |
| Time off treatment (\*)/ Time on treatment (\*\*)  |  | 73.80±24.10 | 18.30±3.25 | 39.66±6.15 | 23.00±5.43 | (‡) |
| CD4+ T-Cell counts  |  | 728.72±97.64 | 961.00±149.68 | 844.00±127.92 | 981.95±118.13 | NS |
| PI-based therapy (%) |  |  | 58 |  | 43 |  |
| NNRTI-based therapy (%) |  |  | 38 |  | 38 |  |
| PI+NNRTI-based therapy (%) |  | 0 |  | 10 |  |
| NRTI-based therapy (%) |  |  | 4 |  | 9 |  |

Results are expressed by mean ± standard error mean (SEM). LD lipodistrophy; HAART highly active antiretroviral therapy; SEM, standard error mean; PI, protease inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; NRTI, nucleoside reverse transcriptase; (\*) in case of HAART-; (\*\*) in case of HAART+. (†) p=0.012 controls vs. BFA+HAART+. (‡) p<0.05 BFA-HAART- vs BFA-HAART+, p<0.01 BFA-HAART+ vs. BFA+HAART-)